{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:03:07Z","timestamp":1789365787915,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl. Int."],"DOI":"10.3389\/ti.2026.17609","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:10:15Z","timestamp":1789362615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reshaping the landscape of HLA desensitization through immune engineering"],"prefix":"10.3389","volume":"39","author":[{"given":"Delphine","family":"Kervella","sequence":"first","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]},{"name":"Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[{"name":"Kidney Transplant Unit, Nephrology Department, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]},{"name":"Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16478","DOI":"10.3389\/ti.2026.16478","article-title":"Long-term HLA-incompatible kidney transplant outcomes","volume":"39","author":"Kahanp\u00e4\u00e4","year":"2026","journal-title":"Transpl Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.3389\/ti.2022.10511","article-title":"European guideline for the management of kidney transplant patients with HLA antibodies: by the European Society for organ transplantation working group","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int"},{"key":"B3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(16)31595-1","article-title":"Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis","volume":"389","author":"Manook","year":"2017","journal-title":"The Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1681\/ASN.2014090894","article-title":"Immune sensitization and mortality in wait-listed kidney transplant candidates","volume":"27","author":"Sapir-Pichhadze","year":"2016","journal-title":"J Am Soc Nephrol JASN"},{"key":"B6","doi-asserted-by":"publisher","first-page":"686271","DOI":"10.3389\/fimmu.2021.686271","article-title":"Current approaches to desensitization in solid organ transplantation","volume":"12","author":"Schinstock","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/tri.13874","article-title":"Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group","volume":"34","author":"Bestard","year":"2021","journal-title":"Transpl Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13886","DOI":"10.3389\/ti.2024.13886","article-title":"Desensitization with imlifidase for HLA-incompatible deceased donor kidney transplantation: a Delphi international expert consensus","volume":"37","author":"Furian","year":"2025","journal-title":"Transpl Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11244","DOI":"10.3389\/ti.2023.11244","article-title":"Imlifidase for kidney transplantation of highly sensitized patients with a positive crossmatch: the French consensus guidelines","volume":"36","author":"Couzi","year":"2023","journal-title":"Transpl Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/j.ekir.2024.07.024","article-title":"Imlifidase in highly sensitized kidney transplant recipients with a positive crossmatch against a deceased donor","volume":"9","author":"Kamar","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"15425","DOI":"10.3389\/ti.2025.15425","article-title":"Five years Follow-up of imlifidase desensitized kidney transplant recipients","volume":"38","author":"Lorant","year":"2025","journal-title":"Transpl Int Off J Eur Soc Organ Transpl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1056\/NEJMc2517277","article-title":"Kidney transplantation after clearing Anti-HLA antibodies with CD19 CAR T cells","volume":"394","author":"Schrezenmeier","year":"2026","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2513428","article-title":"Kidney transplantation in two highly sensitized candidates after CAR T-Cell therapy","volume":"394","author":"Bhoj","year":"2026","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMc2603853","article-title":"T-Cell engager\u2013mediated HLA antibody depletion before kidney transplantation","volume":"395","author":"Schatzl","year":"2026","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-Cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajt.2024.08.004","article-title":"Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates","volume":"25","author":"Torija","year":"2025","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ajt.2025.12.283","article-title":"Dual targeting of B cell compartments using belatacept and daratumumab in highly sensitized kidney transplant candidates: a mechanistic proof-of-concept desensitization trial","author":"Malvezzi","year":"2026","journal-title":"Am J Transpl"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.kint.2026.01.020","article-title":"B-cell maturation antigen-Targeted T-cell engager therapy combined with B-cell depletion for treatment of refractory HLA sensitization","volume":"109","author":"Leon","year":"2026","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ndt\/gfae160","article-title":"Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection","volume":"40","author":"Arana","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ymthe.2025.01.009","article-title":"Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection","volume":"33","author":"Dragon","year":"2025","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/eji.201948144","article-title":"Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies","volume":"50","author":"Cheng","year":"2020","journal-title":"Eur J Immunol"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2026.17609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:10:16Z","timestamp":1789362616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2026.17609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":23,"alternative-id":["10.3389\/ti.2026.17609"],"URL":"https:\/\/doi.org\/10.3389\/ti.2026.17609","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"17609"}}